{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T15:21:42Z","timestamp":1771687302961,"version":"3.50.1"},"reference-count":48,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: Migraine is a common and disabling primary headache disorder, associated with many medical comorbidities, highly prevalent, with complex treatment and management. Currently, monoclonal antibodies targeting the trigeminal sensory neuropeptide, calcitonin gene-related peptide (CGRP), are available. The aim of this protocol is to provide a review comparing the effects and safety profile of different monoclonal antibodies in migraine patients. Methods: The literature search will be performed through the MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), Web of Science and Scopus databases, following the PICO strategy. Real World studies and randomized clinical trials assessing the effect of monoclonal antibodies against CGRP interventions (erenumab, eptinezumab, fremanezumab and galcanezumab) on monthly migraine days (MMD), monthly headache days (MHD), headache impact test (HIT-6) and triptan days of use (TriD) will be included. In Real World studies, the DerSimonian and Laird method will be used to calculate pooled estimates of the mean change difference and in randomized clinical trials, a network meta-analysis will be performed to estimate the comparative effects of different monoclonal antibodies against CGRP. Results: The findings of this study will be reported in a peer-reviewed journal. Conclusions: This study will provide evidence to health professionals on the efficacy and safety of different monoclonal antibodies against CGRP on the outcomes studied.<\/jats:p>","DOI":"10.3390\/ijerph19031753","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:35:17Z","timestamp":1643974517000},"page":"1753","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-7561","authenticated-orcid":false,"given":"Jaime","family":"Fern\u00e1ndez-Bravo-Rodrigo","sequence":"first","affiliation":[{"name":"Health and Social Research Center, Universidad de Castilla\u2014La Mancha, 16071 Cuenca, Spain"},{"name":"Pharmacy Service, Hospital Virgen de la Luz, 16002 Cuenca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-8752","authenticated-orcid":false,"given":"Carlos","family":"Pascual-Morena","sequence":"additional","affiliation":[{"name":"Health and Social Research Center, Universidad de Castilla\u2014La Mancha, 16071 Cuenca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Flor-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Hospital Virgen de la Luz, 16002 Cuenca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Saz-Lara","sequence":"additional","affiliation":[{"name":"Health and Social Research Center, Universidad de Castilla\u2014La Mancha, 16071 Cuenca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-4331","authenticated-orcid":false,"given":"Irene","family":"Sequ\u00ed-Dominguez","sequence":"additional","affiliation":[{"name":"Health and Social Research Center, Universidad de Castilla\u2014La Mancha, 16071 Cuenca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-1618","authenticated-orcid":false,"given":"Celia","family":"\u00c1lvarez-Bueno","sequence":"additional","affiliation":[{"name":"Health and Social Research Center, Universidad de Castilla\u2014La Mancha, 16071 Cuenca, Spain"},{"name":"Universidad Polit\u00e9cnica y Art\u00edstica del Paraguay, Asuncion 001518, Paraguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Barreda-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Hospital Virgen de la Luz, 16002 Cuenca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-0430","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Cavero-Redondo","sequence":"additional","affiliation":[{"name":"Health and Social Research Center, Universidad de Castilla\u2014La Mancha, 16071 Cuenca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","article-title":"The pathophysiology of migraine: Implications for clinical management","volume":"17","author":"Charles","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/head.13459","article-title":"Migraine Progression: A Systematic Review","volume":"59","author":"Buse","year":"2019","journal-title":"Headache"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/head.12725","article-title":"Migraine Triggers and Oxidative Stress: A Narrative Review and Synthesis","volume":"56","author":"Borkum","year":"2016","journal-title":"Headache"},{"key":"ref_5","unstructured":"Pescador Ruschel, M.A., and De Jesus, O. (2021). Migraine Headache, StatPearls Publishing."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1468-2982.2007.01303.x","article-title":"The triggers or precipitants of the acute migraine attack","volume":"27","author":"Kelman","year":"2007","journal-title":"Cephalalgia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrneurol.2017.151","article-title":"Migrainomics\u2014identifying brain and genetic markers of migraine","volume":"13","author":"Nyholt","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ncl.2016.06.011","article-title":"Epidemiology of Migraine","volume":"34","author":"Younger","year":"2016","journal-title":"Neurol. Clin."},{"key":"ref_9","unstructured":"World Health Organization (2021, October 14). Headache Disorders. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/headache-disorders."},{"key":"ref_10","first-page":"282","article-title":"Catastrofizaci\u00f3n ante el dolor y abuso de analg\u00e9sicos en pacientes con migra\u00f1a cr\u00f3nica [Pain catastrophizing and medication overuse in patients with chronic migraine]","volume":"70","author":"Barral","year":"2020","journal-title":"Rev. Neurol."},{"key":"ref_11","first-page":"243","article-title":"Acute Migraine Headache: Treatment Strategies","volume":"97","author":"Mayans","year":"2018","journal-title":"Am. Fam Physician"},{"key":"ref_12","first-page":"72","article-title":"HEART Score for Predicting Adverse Outcomes in Patients with Chest Pain","volume":"98","author":"Gomez","year":"2018","journal-title":"Am. Fam Physician"},{"key":"ref_13","first-page":"157","article-title":"Tratamiento de la migra\u00f1a aguda y cr\u00f3nica y aspectos preventivos","volume":"24","author":"Escuredo","year":"2017","journal-title":"FMC"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies\u2014successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Carmine Belin, A., Ran, C., and Edvinsson, L. (2020). Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache. Brain Sci., 10.","DOI":"10.3390\/brainsci10010030"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mavridis, T., Deligianni, C.I., Karagiorgis, G., Daponte, A., Breza, M., and Mitsikostas, D.D. (2021). Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070700"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: An efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"Vandervorst","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","article-title":"Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: Real-life effectiveness and predictors of response at 6\u2009months","volume":"22","author":"Caronna","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s10194-020-01211-5","article-title":"Immunogenicity of biologic therapies for migraine: A review of current evidence","volume":"22","author":"Cohen","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-020-01097-3","article-title":"Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies","volume":"21","author":"Haanes","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e18483","DOI":"10.1097\/MD.0000000000018483","article-title":"Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials","volume":"98","author":"Zhu","year":"2019","journal-title":"Medicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","article-title":"Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety","volume":"79","author":"Lattanzi","year":"2019","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105900","DOI":"10.1016\/j.clineuro.2020.105900","article-title":"Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis","volume":"195","author":"Alasad","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Deng, H., Li, G.G., Nie, H., Feng, Y.Y., Guo, G.Y., Guo, W.L., and Tang, Z.P. (2020). Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine -an updated systematic review and meta-analysis. BMC Neurol., 20.","DOI":"10.1186\/s12883-020-01633-3"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10072-018-3547-3","article-title":"The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: A meta-analysis","volume":"39","author":"Zhu","year":"2018","journal-title":"Neurol Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1080\/01616412.2021.1940672","article-title":"Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine","volume":"43","author":"Shi","year":"2021","journal-title":"Neurol Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106893","DOI":"10.1016\/j.clineuro.2021.106893","article-title":"Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis","volume":"209","author":"Soni","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"649143","DOI":"10.3389\/fphar.2021.649143","article-title":"Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"117505","DOI":"10.1016\/j.jns.2021.117505","article-title":"Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials","volume":"427","author":"Masoud","year":"2021","journal-title":"J. Neurol Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/picr.picr_62_21","article-title":"Introduction to real-world evidence studies","volume":"12","author":"Chodankar","year":"2021","journal-title":"Perspect. Clin. Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Li, T., Puhan, M.A., Vedula, S.S., Singh, S., and Dickersin, K. (2011). Network meta-analysis-highly attractive but more methodological research is needed. BMC Med., 9.","DOI":"10.1186\/1741-7015-9-79"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: Aproposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.medcli.2016.02.025","article-title":"La extensi\u00f3n de la declaraci\u00f3n PRISMA para revisiones sistem\u00e1ticas que incorporan metaan\u00e1lisis en red: PRISMA-NMA","volume":"147","author":"Hutton","year":"2016","journal-title":"Med. Clin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"ref_36","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2022, January 30). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane. Available online: www.training.cochrane.org\/handbook."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0140-6736(10)60903-8","article-title":"An international registry of systematic-review protocols","volume":"377","author":"Booth","year":"2011","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence pro les and summary of ndings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_42","first-page":"50","article-title":"Understanding GRADE: An introduction","volume":"6","author":"Goldet","year":"2013","journal-title":"JBEM"},{"key":"ref_43","unstructured":"Sutton, A.J., Abrams, K.R., Jones, D.R., Sheldon, T.A., and Song, F. (2000). Methods for Meta-Analysis in Medical Research, John Wiley & Sons, Ltd."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.03.007","article-title":"The number needed to treat in pairwise and network meta-analysis and its graphical representation","volume":"111","author":"Veroniki","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"a1331","DOI":"10.1136\/bmj.a1331","article-title":"Drug eluting and bare metal stents in people with and without diabetes: Collaborative network meta-analysis","volume":"337","author":"Stettler","year":"2008","journal-title":"BMJ"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"Br. Med. J."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/3\/1753\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:13:45Z","timestamp":1760134425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/3\/1753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijerph19031753"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19031753","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}